TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04967183

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Annual FIT
Description: Patients will be offered an annual FIT and colonoscopy will be performed if fecal hemoglobin concentration is ≥10µg / g of feces. After performing a colonoscopy the FIT will be sent to the patient:~* After one year if the unscheduled colonoscopy has been incomplete or a lesion requiring endoscopic surveillance has been completely resected.~* After five years if the colonoscopy has evaluated the entire mucosa, it is normal or with lesions that do not require endoscopic surveillance (1-2 non-advanced adenomas).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic surveillance.
Description: First surveillance colonoscopy will be performed in three-year time. If an advanced adenoma or at least three non-advanced adenomas are detected, colonoscopy will be repeated after 3 years. In contrast, if colonoscopy is normal or 1-2 non-advanced adenomas are detected, colonoscopy will be repeated after 5 years.
Study: NCT06313554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib、Toripalimab、Gemcitabine、Oxaliplatin
Description: The first week dose of Surufatinib was 150mg, the second week and the subsequent cycle was 200 mg once a day (QD) orally, Q3W, and the drug was suspended for one day on the day of HAIC; Toripalimab: 240mg intravenous infusion d1, Q3W;~HAIC: All patients received HAIC treatment on D1. Hepatic arterial perfusion therapy (HAIC) : a treatment cycle every 3 weeks for 4-6 consecutive cycles:~Surufatinib and Toripalimab were administered continuously until intolerable toxicity, disease progression, withdrawal of informed consent, loss of follow-up, and investigator judgment that medication should be discontinued (whichever occurred first).
Study: NCT06111001

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Email use data collection
Description: Participants will initiate the AirEmail v1 Digital Tool. Non-identifiable email use data will be collected.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Email use data collection
Description: Participants will initiate the AirEmail v1 Digital Tool. Non-identifiable email use data will be collected.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AirEmail Tips and Tricks training
Description: Participants will watch the AirEmail Tips and Tricks training videos ahead of using the AirEmail v1 Digital Tool

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AirEmail v1 Digital Tool use
Description: Participants will use the AirEmail v1 Digital Tool features as part of their routine email management in NHSmail, the NHS's Microsoft 365 Outlook platform.
Study: NCT05388422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of 3D scanner to measure physical size in patients with severe cerebral palsy
Description: Before starting the study, radiologic and clinical evaluation were performed. After measuring the patient's exact physical size by applying a 3D scanner, we manufacture hip brace in preventing progressive hip displacement in patients with severe cerebral palsy. After wearing for a week, follow-up radiologic and clinical evaluation were performed.
Study: NCT05881122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mad Dog Dietary Consultation
Description: The Mad Dog consultation was delivered in two parts over consecutive days. Part I entailed an accompanied trip to the participant's preferred grocery store to show the participant where selected foods could be found, how to read nutrition labels so that acceptable substitutions to the Mad Dog ingredients could be made, and how to shop for value when choices are presented. Part II of the consultation occurred in the participant's home and focused on meal preparation and kitchen accessibility, as well as a brief overview regarding the negative consequences of chronic inflammation, and the positive effects of adopting an anti-inflammatory diet. Questions and discussion were highly encouraged throughout the consultation and materials were left with the participants allowing them to easily review and reference information that was covered during the meeting. Specifically, participants were given 28 compliant recipes, additional snack ideas and shopping tips along with a consult summary.
Study: NCT06006598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1584862
Description: BI 1584862

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BI 1584862
Description: Placebo matching BI 1584862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: midazolam
Study: NCT05326256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training- PSSE
Description: Barcelona Scoliosis Physical Therapy School (BSPTS) method exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training- PSSE with vestibular exercises
Description: Vestibular exercises added to Barcelona Scoliosis Physical Therapy School (BSPTS) exercises
Study: NCT05008471

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formula nutrition
Description: The target energy of radiotherapy patients is recommended to be 25-30kcal/(kg·d), and the target energy of the intervention group should be increased by an additional 50% daily from the beginning of radiotherapy. Specifically, under the condition of ensuring the daily target energy 14kcal/(kg·d), formula nutrition should be added daily.
Study: NCT05008159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3 month community-based mobility and health intervention
Description: 12 weekly GROUP (10-15 adults per cohort) sessions + 3 INDIVIDUAL tailored system navigation sessions at beginning, midpoint, and end of program.~The 3-month GROUP program will include the following fixed components:~i) weekly interactive group-based health education sessions focused on:~* increasing knowledge, skills, and behaviours related to physical activity, healthy eating, and available community supports for older adults;~* socialization to foster peer and community connections, co-learning, and decrease social isolation~* skill-building to support independence and quality of life; and~ii) INDIVIDUAL tailored system navigation support
Study: NCT04924140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab
Description: Administered as specified in the treatment arm
Study: NCT06389383

Intervention type: OTHER
Group type: OTHER
Intervention: Nasal Swab
Description: * Nasal swab once a week for the duration of the stay in intensive care unit/intensive care (procedure already carried out routinely to detect nasal staphylococcus once a week).~* Nasal swab every 14 days when the newborn is hospitalized in routine care/kangaroo unit/hospitalization at home
Study: NCT04926506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiyanping injection
Description: Intramuscular injection of Xiyanping injection, 0.3mL / (kg.d) daily, Bid
Study: NCT06274151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen 500 Mg
Description: Attenuating the sub-acute inflammatory processes to monitor potential beneficial tissue healing following a muscle strain injury

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Rehabilitation after muscle strain injury

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitation after muscle strain injury

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sub-acute inflammatory processes not attenuated. Group will be treated as control to monitor tissue healing following a muscle strain injury without pharmacological intervention.
Study: NCT04715217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD22 CAR-T cells
Description: A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD22 CAR-T cells
Description: A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD22 CAR-T cells
Description: A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD22 CAR-T cells
Description: A autologous doping CAR - T cells injection targets with CD19 and CD22，fluorine dara marina injection(30 mg/m2，QD×3d) and cyclophosphamide injection (300 mg/m2，QD×3d)will be used to remove the lymphocyte before infusion CD19-CD22 CAR-T cells .
Study: NCT04460963

Intervention type: OTHER
Group type: OTHER
Intervention: Adrenomedullin
Description: Adrenomedullin sample evaluation
Study: NCT05461365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Gelfoam® cottonoids soaked in 40 IU of NPH insulin were placed on the nasal roof (between the nasal septum and the middle meatus) of each nostril. These remained in place for 15 minutes and were later removed. This procedure was performed in three visits one week apart. During the fourth and last visit (one week after the previous visit), olfaction was reevaluated using the measures previously described.
Study: NCT04850235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab paclitaxel plus cisplatin and capecitabine as neoadjuvant chemotherapy
Study: NCT04354168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Application
Description: Nthabi mHealth Application delivers educational content and recommendations to minimize or eliminate health risks. The content is delivered via the Nthabi application downloaded on an Android phone smartphone. End-users can select from a list of topics relevant to the Lesotho population to engage with the conversational agent, Nthabi, and discuss conditions such as tuberculosis, HIV testing, healthy diet, and family planning.
Study: NCT05742048

Intervention type: DIAGNOSTIC_TEST
Intervention: traumatic patient suspect to have long bone fracture between 18 - 65 years old
Description: Number of patients diagnosed to have a long bone fracture by using ultrasound. Number of patients diagnosed to have a long bone fracture by using x-ray . Comparison between Ultrasound bone scan result and X-ray imaging accuracy and sensitivity.
Study: NCT05656885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A
Description: Soft spherical hydrogel contact lens for 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B
Description: Soft spherical silicone hydrogel contact lens for 15 minutes
Study: NCT06021587

Intervention type: DRUG
Intervention: Levosimendan
Description: Initiation of levosimendan 48 hours before surgery

Intervention type: DRUG
Intervention: No Levosimendan
Description: Without Levosimendan Infusion
Study: NCT05742191

Intervention type: OTHER
Intervention: Daylight Savings time transitions
Description: Daylight Savings time transitions.
Study: NCT04073797

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inclisiran
Description: Inclisiran 284 mg, one injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran 284 mg, one injection

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: 68Ga-DOTATATE PET-MRI
Description: 68Ga-DOTATATE PET-MRI at baseline and 12 weeks

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 68Ga-DOTATATE PET-MRI
Description: 68Ga-DOTATATE PET-MRI at baseline and 12 weeks

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE PET-MRI
Description: 68Ga-DOTATATE PET-MRI at baseline and 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine 500 mcg tablet once daily
Study: NCT05930808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First Test Concor (Fasted)
Description: Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First Reference Concor (Fasted)
Description: Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First Test Concor (Fed)
Description: Participants will receive single oral dose of Test Concor tablet under fasted or fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First Reference Concor (Fed)
Description: Participants will receive single oral dose of Reference Concor tablet under fasted or fed condition.
Study: NCT05217355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBA-P01 (Botulinum toxin A)
Description: MBA-P01 will be injected into the Glabellar line

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be injected into the Glabellar line
Study: NCT05696223

Intervention type: OTHER
Intervention: Ultrasound
Description: Doppler mesure

Intervention type: OTHER
Intervention: Ultrasound
Description: Doppler mesure
Study: NCT04574232

Intervention type: DRUG
Group type: OTHER
Intervention: knee intra-articular infiltration with Triamcinolone acetonide
Description: knee intra-articular intra-articular ultrasound-guided infiltration of Triamcinolone acetonide
Study: NCT05287854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset
Description: Once the patient is on the operating table, the nurse proposes the different possible VR scenarios and installs the RV headset and an audio headset.
Study: NCT04886817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilot Intervention to reduce SSB consumption in children and families
Description: A 6-month intervention based on the use of 4 components: an educational video, provision of a water-promotion toolkit, a mobile phone application (app), and a series of 14 computerized interactive voice response (IVR) phone calls to parents to compare families' SSB's consumption behaviors
Study: NCT05760911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outdoor activities motivation with smartwatches
Description: Wearing a smartwatch and receiving outdoor activity reminders and encouragement through a mini-program. The required outdoor time is at least 2 hours from Monday to Friday, and more than 2 hours on weekends.
Study: NCT03596242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS System
Description: Participants will receive usual care +SMS texting and phone calls to monitor their blood pressure and medication adherence

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blood pressure control education
Description: standard blood pressure control education given during visits

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: blood pressure control education
Description: standard blood pressure control education given during visits
Study: NCT05476510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative management
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative management
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.
Study: NCT05810805

Intervention type: OTHER
Intervention: gas component of digestive tract
Description: Analyze the differences in gas components in different segments of the digestive tract in patients with different diseases, and analyze the correlation between specific gases and digestive tract diseases and non-specific symptoms.

Intervention type: OTHER
Intervention: gas component of digestive tract
Description: Analyze the differences in gas components in different segments of the digestive tract in patients with different diseases, and analyze the correlation between specific gases and digestive tract diseases and non-specific symptoms.

Intervention type: OTHER
Intervention: gas component of digestive tract
Description: Analyze the differences in gas components in different segments of the digestive tract in patients with different diseases, and analyze the correlation between specific gases and digestive tract diseases and non-specific symptoms.

Intervention type: OTHER
Intervention: gas component of digestive tract
Description: Analyze the differences in gas components in different segments of the digestive tract in patients with different diseases, and analyze the correlation between specific gases and digestive tract diseases and non-specific symptoms.

Intervention type: OTHER
Intervention: gas component of digestive tract
Description: Analyze the differences in gas components in different segments of the digestive tract in patients with different diseases, and analyze the correlation between specific gases and digestive tract diseases and non-specific symptoms.

Intervention type: OTHER
Intervention: gas component of digestive tract
Description: Analyze the differences in gas components in different segments of the digestive tract in patients with different diseases, and analyze the correlation between specific gases and digestive tract diseases and non-specific symptoms.
Study: NCT06090175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Projector colleyscope group
Description: Projector kaleidoscope will be used in children aged 3-6 who are administered inhaler medication.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching card group
Description: Matching card will be used in children aged 3-6 who are administered inhaler medication.
Study: NCT04678908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0025
Description: Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0025 via intravenous infusion.
Study: NCT05283356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 60mg
Description: Ticagrelor 60mg BID after TAVI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60mg
Description: Ticagrelor 60mg BID after TAVI
Study: NCT04692376

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Mesenchymal stem cells (MSCs) will be intravenously infused via a central venous catheter(at a dose of 1×10\^6 cells/kg, over 15 mins) weekly. MSCs will be administrated for 8 doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Glucocorticoids (i.e. Methylprednisolone) will be used with an initial dose of 1mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Glucocorticoids (i.e. Methylprednisolone) will be used with an initial dose of 1mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporine
Description: Cyclosporine (CsA) will be used with an initial dose of 2.5mg/kg/d and adjusted according to the concentration of CsA. The targeted concentration is 200-300 ng/Ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Cyclosporine (CsA) will be used with an initial dose of 2.5mg/kg/d and adjusted according to the concentration of CsA. The targeted concentration is 200-300 ng/Ml.
Study: NCT05550571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nautilus Intrasaccular Bridging System
Description: Patients will be treated with the Nautilus, then followed-up for 12 months
Study: NCT06198699

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jing Si Herbal Tea
Description: Consuming Jing Si Herbal Tea for three months; twice per day with each time 14 g of Jing Si Herbal in 600 ml water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Barley Tea
Description: Consuming Barley Tea for three months; twice per day with each time 600 ml barley tea consumption
Study: NCT05376345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-BCDR cells product
Description: Before treatment with LCAR-BCDR cells, subjects will receive a conditioning regimen
Study: NCT05439473

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Curalin
Description: Supplement capsules, 2 capsules, 3 times a day after meals. Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curalin
Description: Supplement capsules, 2 capsules, 3 times a day after meals. Placebo: matching placebo capsules, 2 capsules, 3 times a day after meals.
Study: NCT06402578

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HbA1c testing
Description: Bloods will be take pre and post 12 week intervention.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HbA1c testing
Description: Bloods will be take pre and post 12 week intervention.
Study: NCT05720377

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous glucose monitor (Freestyle Libre
Description: 15 minute phone interview by health care provider to assess health goals set at clinic visits.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous glucose monitor (Freestyle Libre
Description: 15 minute phone interview by health care provider to assess health goals set at clinic visits.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous glucose monitor (Freestyle Libre
Description: 15 minute phone interview by health care provider to assess health goals set at clinic visits.
Study: NCT04431245

Intervention type: DRUG
Intervention: Entecavir
Description: Study subjects will stop the antiviral therapy. Patients will be closely monitored every 6-8 weeks for virological flare and/or biochemical flare.